ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1430

Anti-SOD2 Antibodies in Lupus Nephritis as Second Wave Antibodies

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Angeletti, Andrea, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Bruschi, Maurizio, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Lugani, Francesca, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Caridi, Gianluca, Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Verrina, Enrico E., Istituto Giannina Gaslini, Genova, Liguria, Italy
  • Ghiggeri, Gian Marco, Istituto Giannina Gaslini, Genova, Liguria, Italy

Group or Team Name

  • ZEUS Study

Superoxide dismutase-2 (SOD2) is an enzyme with antioxidant action. Anti-SOD2 antibodies (anti-SOD2 IgG2) were recently described in the serum of subjects with Membranous Nephropathy, as antigens of a possible second wave injury. The presence of anti-SOD2 IgG2 correlated with worse outcomes in terms of response to treatment [1]. The presence and role of anti-SOD2 IgG2 in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), a secondary autoimmune glomerulonephritides, are to be clarified.


We measured serum levels of anti-SOD2 IgG2 (Homemade designed ELISA), every six months, in 1.052 patients (459 LN and 573 SLE) enrolled at different times from the diagnosis (i.e., 0-1 month, 2-12 m, 13-24 m, 25-48 m, 49-96 m, and >96 m). We also evaluated the main markers of the SLE activity, such as serum complement C3 and C4, ANA, ENA, anti-dsDNA and proteinuria. Of note, 91 LN and 130 SLE had a relevant follow-up of 36 months.


As main characteristics, we report median age of 40 (IQR 28-54) years, the predominance of females (88%), disease activity (SLEDAI) of 4 (IQR 2-8).
At the cross-sectional analysis, serum levels of anti-SOD2 IgG2 at T0 are significantly higher in LN than in SLE (Fig 1a). Considering LN, the serum levels of anti-SOD2 IgG2 at T0 were significantly higher than the other time points (Fig 1a). No correlation with the histological class of LN is reported. In LN, the reduction of anti-SOD2 IgG2 was in accordance with proteinuria. Anti-dsDNAs did not result as a valuable marker of disease activity (Fig 1b).


Circulating anti-SOD2 IgG2 are elevated in active LN.
Serum levels of Anti-SOD2 IgG2, also considering the concomitant negative serum levels of anti-dsDNAs in all phases of LN, support the hypothesis of direct involvement of anti-SOD2 antibodies in LN as second wave antibodies that actively contribute to the manifestations of autoimmune glomerulonephritides.